Disclosures: Ronald P. DeMatteo is a consultant to and has received honoraria from Novartis.
Metastasectomy for gastrointestinal stromal tumors
Article first published online: 24 OCT 2013
© 2013 Wiley Periodicals, Inc.
Journal of Surgical Oncology
Special Issue: Seminars in Surgical Oncology: Role of Surgical Metastasectomy in Oncologic Practice
Volume 109, Issue 1, pages 23–27, January 1, 2014
How to Cite
Bamboat, Z. M. and DeMatteo, R. P. (2014), Metastasectomy for gastrointestinal stromal tumors. J. Surg. Oncol., 109: 23–27. doi: 10.1002/jso.23451
- Issue published online: 13 DEC 2013
- Article first published online: 24 OCT 2013
- Manuscript Accepted: 10 SEP 2013
- Manuscript Received: 21 JAN 2013
- gastrointestinal stromal tumor;
- tyrosine kinase;
Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the intestinal tract. Improvements in understanding the molecular pathogenesis of GIST have resulted in novel treatment strategies combining surgery with tyrosine kinase inhibitors (TKIs). Metastasectomy in carefully selected patients who have stable or responsive disease on imatinib should be considered in the multidisciplinary setting. We review existing data on surgical cytoreduction in metastatic GIST while on targeted therapy and compare outcomes with either treatment alone. J. Surg. Oncol. 2014 109:23–27. © 2013 Wiley Periodicals, Inc.